DE2222092A1 - Antigene Substanz zur Pruefung auf Tuberkulose und Verfahren zur Herstellung derselben - Google Patents
Antigene Substanz zur Pruefung auf Tuberkulose und Verfahren zur Herstellung derselbenInfo
- Publication number
- DE2222092A1 DE2222092A1 DE19722222092 DE2222092A DE2222092A1 DE 2222092 A1 DE2222092 A1 DE 2222092A1 DE 19722222092 DE19722222092 DE 19722222092 DE 2222092 A DE2222092 A DE 2222092A DE 2222092 A1 DE2222092 A1 DE 2222092A1
- Authority
- DE
- Germany
- Prior art keywords
- fractions
- fraction
- antigens
- sub
- chromatographic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000012360 testing method Methods 0.000 title claims description 35
- 238000000034 method Methods 0.000 title claims description 24
- 230000000890 antigenic effect Effects 0.000 title claims description 14
- 239000000126 substance Substances 0.000 title claims description 14
- 201000008827 tuberculosis Diseases 0.000 title description 4
- 230000008569 process Effects 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 2
- 239000000427 antigen Substances 0.000 claims description 99
- 102000036639 antigens Human genes 0.000 claims description 99
- 108091007433 antigens Proteins 0.000 claims description 99
- 239000000706 filtrate Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 11
- 238000004255 ion exchange chromatography Methods 0.000 claims description 7
- 238000001155 isoelectric focusing Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 206010070834 Sensitisation Diseases 0.000 claims description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- 230000008313 sensitization Effects 0.000 claims description 4
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 241000700198 Cavia Species 0.000 description 14
- 239000000463 material Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000000951 immunodiffusion Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 229960001005 tuberculin Drugs 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 4
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 206010006049 Bovine Tuberculosis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 241001506930 atypical mycobacterium Species 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/806—Electrical property or magnetic property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/140,444 US3969497A (en) | 1971-05-05 | 1971-05-05 | Test substance for tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2222092A1 true DE2222092A1 (de) | 1972-11-16 |
Family
ID=22491246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722222092 Withdrawn DE2222092A1 (de) | 1971-05-05 | 1972-05-05 | Antigene Substanz zur Pruefung auf Tuberkulose und Verfahren zur Herstellung derselben |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US3969497A (OSRAM) |
| CA (1) | CA991992A (OSRAM) |
| DE (1) | DE2222092A1 (OSRAM) |
| FR (1) | FR2135284B1 (OSRAM) |
| GB (1) | GB1385087A (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436824A (en) | 1981-06-09 | 1984-03-13 | Ortho Diagnostic Systems, Inc. | Leukocyte migration through antigen containing agaroses for immunocompetence testing |
| CA1299099C (en) * | 1986-03-06 | 1992-04-21 | Paul Richard Wood | In vitro assay for detecting cell-mediated immune responses |
| US5344759A (en) * | 1992-05-11 | 1994-09-06 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health & Welfare | Glycolipids for serodiagnosis of tuberculosis and leprosy |
| US5985847A (en) * | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
| WO2007041539A1 (en) | 2005-09-30 | 2007-04-12 | Transcutaneous Technologies, Inc. | Iontophoresis apparatus and method for the diagnosis of tuberculosis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE487199C (de) * | 1927-02-12 | 1929-12-03 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von gereinigten Tuberkulinpraeparaten |
| US2204272A (en) * | 1938-04-25 | 1940-06-11 | Lakeland Foundation | Antigen for determination of tuberculosis and process of making the same |
| US2901398A (en) * | 1952-06-19 | 1959-08-25 | Mount Sinai Hospital Res Found | Ion-exchange purification of allergenic pollen component |
| US3105012A (en) * | 1961-10-19 | 1963-09-24 | Parke Davis & Co | Antigen products and means for producing the same |
-
1971
- 1971-05-05 US US05/140,444 patent/US3969497A/en not_active Expired - Lifetime
-
1972
- 1972-05-04 FR FR7215877A patent/FR2135284B1/fr not_active Expired
- 1972-05-04 GB GB2089772A patent/GB1385087A/en not_active Expired
- 1972-05-05 DE DE19722222092 patent/DE2222092A1/de not_active Withdrawn
- 1972-05-05 CA CA141,428A patent/CA991992A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US3969497A (en) | 1976-07-13 |
| CA991992A (en) | 1976-06-29 |
| FR2135284B1 (OSRAM) | 1975-12-26 |
| GB1385087A (en) | 1975-02-26 |
| FR2135284A1 (OSRAM) | 1972-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3853854T2 (de) | Vakzin gegen Neisseria meningitidis Gruppe-B, Gammaglobulin und Transferfaktor. | |
| DE3346336C2 (OSRAM) | ||
| DE112011102409T5 (de) | Verfahren zur Behandlung der Alzheimer-Krankheit | |
| DE112011102411T5 (de) | Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung | |
| DE2817871A1 (de) | Verfahren und vorrichtung zur abtrennung und reinigung von proteinen durch chromatographie | |
| DE2458465A1 (de) | Verfahren zur herstellung eines lyophilisierten normalen humanurins zur arzneimittelkontrolle | |
| DE3024282A1 (de) | Vakzinierende glycopeptid-antigenfraktion mit grosser immunisierungsfaehigkeit, isoliert aus kulturen pathogener keime, verfahren zur isolierung dieser fraktion und diese enthaltende vakzinen | |
| DE2222092A1 (de) | Antigene Substanz zur Pruefung auf Tuberkulose und Verfahren zur Herstellung derselben | |
| DE2355094A1 (de) | Tetanus-vaccine und verfahren zu deren herstellung | |
| DE69220939T2 (de) | Gegengift immunsera | |
| DE2518474A1 (de) | Mitogenes mittel, verfahren zu seiner herstellung und diese mittel enthaltende arzneimittel und biologische reagenzien | |
| DE69532964T2 (de) | Neue proteine aus ektoparasitenspeichel und vorrichtung zur sammlung davon | |
| DE2262427C3 (de) | Immunostimulierendes Mittel | |
| DE2605576B2 (de) | Verfahren zum Isolieren der Proteasen Papain, Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papaya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und lyophilisierten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten | |
| CH650154A5 (de) | Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. | |
| DE3882061T2 (de) | Verfahren zum Extrahieren von Membranantigenen mit immunogenen Eigenschaften aus humanen neoplastischen Zellen und so erhaltene Produkte. | |
| EP1478662B1 (de) | Verfahren zur herstellung von hypoallergenem birkenpollenhauptallergen rbet v 1 | |
| DE3720232C2 (de) | Verfahren zur Herstellung eines Extraktes aus Aloe-Blättern der Pflanzengattung Aloe capensis oder Aloe arborescens | |
| Aach | Serologische Untersuchungen an Mutanten des Tabakmosaikvirus | |
| DE69026275T2 (de) | Verfahren zur herstellung von ribonuklease-dimeren | |
| DE2110436C3 (de) | Verfahren zur Herstellung eines antileukopenischen und antikörperbildenden Thymusextrakts aus Kalbsthymus | |
| DE1910715A1 (de) | Antimikrobielle Faktoren und deren Verwendung | |
| DE10007771A1 (de) | Immunmodulatorisch wirksame Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2533183C3 (de) | Verfahren zum Herstellen gereinigter Immunglobuline | |
| DE229131C (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: MERIEUX LABORATORIES, INC., ATLANTA, GA., US |
|
| 8127 | New person/name/address of the applicant |
Owner name: LINCOLN LABORATORIES, INC. (EINE GESELLSCHAFT N.D. |
|
| 8128 | New person/name/address of the agent |
Representative=s name: WUESTHOFF, F., DR.-ING. FRHR. VON PECHMANN, E., DI |
|
| 8130 | Withdrawal |